Last update 27 Nov 2024
JSKN-003/Envafolimab
Last update 27 Nov 2024
Overview
Basic Info
Drug Type Nanobody, Antibody drug conjugate (ADC) |
Synonyms JSKN003/Envafolimab, JSKN 033, JSKN003/KN035 + [1] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC38H43N9O8 |
InChIKeyQODRVHFOPFCZOM-IUDBTDONSA-N |
CAS Registry- |
Gene Sequence
Sequence Code 315610456H
The sequence is quoted from: *****
Related
1
Clinical Trials associated with JSKN-003/EnvafolimabPhase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
100 Clinical Results associated with JSKN-003/Envafolimab
Login to view more data
100 Translational Medicine associated with JSKN-003/Envafolimab
Login to view more data
100 Patents (Medical) associated with JSKN-003/Envafolimab
Login to view more data
100 Deals associated with JSKN-003/Envafolimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Solid Tumors | Phase 2 | AU | 26 Mar 2024 | |
| Solid tumor | Phase 2 | AU | 18 Jan 2024 | |
| Neoplasms | IND Application | CN | 19 Nov 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 10 | brzjoxonmb(rtebwxjhoj) = The most common was mild to moderate injection site reactions (Grade 1–2). cgfwjptttx (umqblcpwcr ) View more | Positive | 05 Nov 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free